Letters Adjuvant trastuzumab for breast cancer: Assessing HER2/neu status incurs more costs for treatment BMJ 2005; 331 doi: https://doi.org/10.1136/bmj.331.7526.1202 (Published 17 November 2005) Cite this as: BMJ 2005;331:1202 Article Related content Metrics Responses Peer review Related articles Editorial Adjuvant trastuzumab for breast cancer Published: 03 November 2005; BMJ 331 doi:10.1136/bmj.331.7524.1035 See more Constitutional symptoms in a young person BMJ December 07, 2016, 355 i5781; DOI: https://doi.org/10.1136/bmj.i5781 An adolescent with disabling abdominal pain BMJ December 07, 2016, 355 i6101; DOI: https://doi.org/10.1136/bmj.i6101 Andrew Wakefield calls Trump “on our side” over vaccines after meeting BMJ December 05, 2016, 355 i6545; DOI: https://doi.org/10.1136/bmj.i6545 Doctors in Pakistan call for workers deported from the UAE to be screened for HIV BMJ December 05, 2016, 355 i6544; DOI: https://doi.org/10.1136/bmj.i6544 Communicating risk to patients in the emergency department BMJ December 05, 2016, 355 i6437; DOI: https://doi.org/10.1136/bmj.i6437
